Loading profile
Loading sourced facts.
01 Finding sources
02 Reading evidence
03 Filing the card
Loading profile
01 Finding sources
02 Reading evidence
03 Filing the card
Perceptic sells an AI data-integration layer to big pharma R&D teams that connects proprietary, public, and purchased datasets across the full drug-development lifecycle—from asset scouting through clinical trial design.
Raised $12M across disclosed rounds.[1][2]
Seed closed May 2026, led by Accel.[1][2]
post-money valuation is not publicly disclosed.
Named investors include Accel, Air Street Capital, Elder Gull.[1]
Tilman Flock, Co-founder & CEO[1]
Martin Copes, Co-founder[1]
Zaki Trache, Co-founder[1]
Tilman Flock, CEO[1]
May 2026 · dnyuz.com
reported
May 2026 · fortune.com
reported
Perceptic sells an AI data-integration layer to big pharma R&D teams that connects proprietary, public, and purchased datasets across the full drug-development lifecycle—from asset scouting through clinical trial design.
Ask for one referenceable production customer.
Not a recommendation. The first thing this ledger cannot answer.
Isomorphic Labs · isomorphiclabs.com · Same buyer (big pharma R&D), same macro category (AI for drug discovery), but Isomorphic focuses on molecular-level point tools (structure prediction, molecule design) rather than cross-stage data integration—Perceptic explicitly positions against this...[1]
Recursion Pharmaceuticals · recursion.com · Same buyer segment and AI-for-drug-discovery category; Recursion is a point-tool competitor (wet-lab automation + ML) that Perceptic's CEO cited as an example of the siloed approach Perceptic is designed to bridge.[1]
Insilico Medicine · insilico.com · Named by CEO as representative of the point-tool cohort Perceptic differentiates from; same pharma R&D buyer but focused on specific discovery stages rather than cross-lifecycle data orchestration.[1]
Palantir Technologies (AIP for Life Sciences) · palantir.com · Closest workflow overlap: all three Perceptic founders built Palantir's AIP and its life sciences commercial practice. Perceptic is effectively a purpose-built, pharma-native alternative to Palantir AIP—same data-harmonization wedge, same pharma R&D buyer,...[1]
The customer proof is company-sourced only. No independent source in this ledger confirms it.[4]
Ask for one referenceable production customer.
Not a recommendation. The first thing this ledger cannot answer.
Filled in the side panel for invited readers. This card carries sourced facts only.
May 2026 · open.endole.co.uk
unknown
May 2026
vendor
May 2026 · perceptive.com
reported